On Tuesday, Needham made an adjustment to CRISPR Therapeutics (NASDAQ:CRSP) stock price target, reducing it to $84 from the previous $88, while still endorsing the stock with a Buy rating. The alteration comes after CRISPR Therapeutics reported no sales for Casgevy in the second quarter of 2024.
Despite the lack of sales, there was progress in patient engagement, with approximately 20 patients having had cells collected for treatment, an increase from five in the first quarter of 2024. More than 35 Authorized Treatment Centers (ATCs) are now operational.
The firm has revised its sales projections for Casgevy, forecasting $17 million for the fiscal year 2024, a decrease from the initially expected $43 million. The forecast for fiscal year 2025 has also been adjusted to $182 million from the earlier estimate of $304 million. These changes reflect a more conservative outlook for the near-term revenue potential of Casgevy in sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT).
CRISPR Therapeutics is currently advancing its pipeline with CTX131 and CTX112, which have entered Phase I studies for relapsed/refractory hematologic malignancies and Systemic Lupus Erythematosus (SLE), respectively.
Furthermore, initial results for CTX112 in B-cell lymphoma (BCL) are expected to be released in the second half of 2024. The company's latest in vivo programs, CTX340 and CTX350, were announced earlier this year and are anticipated to commence clinical trials in the second half of 2025.
The biotechnology company concluded the second quarter of 2024 with a strong cash position of $2 billion. The maintained Buy rating reflects Needham's continued confidence in CRISPR Therapeutics' long-term potential, despite the near-term adjustments to the revenue estimates for its lead product, Casgevy.
In other recent news, CRISPR Therapeutics has seen several financial firms adjust their outlooks. Stifel reduced its price target for the company to $59, citing concerns about near-term revenue prospects and upcoming clinical data.
RBC Capital Markets also decreased its target price to $60, following updates on CRISPR's product launches and clinical trials. However, Piper Sandler maintained a consistent price target of $105, highlighting the progression of CRISPR's Phase I/II study for its allogeneic CD19 CAR-T therapy, CTX112.
Meanwhile, Oppenheimer adjusted its price target for CRISPR to $95.00, following the company's first-quarter 2024 financial report that disclosed operating expenses of $141.1 million. In addition to these financial updates, CRISPR announced key executive appointments, with Dr. Naimish Patel assuming the role of Chief Medical Officer and Julianne Bruno being promoted to Chief Operating Officer.
These are recent developments in CRISPR Therapeutics' ongoing efforts to advance its gene editing pipeline. The company continues to make strides in its gene editing pipeline, with several financial firms adjusting their outlooks on the company. Despite the adjustments in the target price, all the firms maintained their ratings on the stock, showcasing a cautious but optimistic outlook for CRISPR Therapeutics.
InvestingPro Insights
In light of Needham's recent price target adjustment for CRISPR Therapeutics, it's pertinent to consider additional insights provided by InvestingPro. The company holds a strong liquidity position, as indicated by the fact that it has more cash than debt on its balance sheet. This financial stability is crucial for CRISPR Therapeutics as it continues to navigate the challenges of bringing its products to market and scaling up patient engagement.
InvestingPro data shows a market cap of $4.22 billion for CRISPR Therapeutics, which, despite a downward trend in stock price over the last week, still maintains a fair value estimate of $53.14 according to InvestingPro's metrics.
It is noteworthy that analysts have revised their earnings upwards for the upcoming period, hinting at an underlying confidence in the company's potential to rebound. However, they also anticipate a sales decline in the current year and do not expect the company to be profitable within this timeframe.
For those seeking a deeper analysis, InvestingPro offers additional tips, including insights on the company's gross profit margins and net income projections. With 7 more InvestingPro Tips available, investors can gain a comprehensive understanding of CRISPR Therapeutics' financial health and market position.
These InvestingPro insights offer a balanced view that complements the information provided by Needham and may help investors make more informed decisions regarding CRISPR Therapeutics' stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.